Muhammad Azmat Khan

Learn More
4530 Background: RAD001 an oral serine-threonine kinase inhibitor of mTOR, blocks progression from the GI to the S phase of the cell cycle by a mechanism of action that is unique for an anticancer drug. Mechanistically, it is thought that RAD001 may play a role in VEGF inhibition. Main endpoints were to evaluate: time to progression (TTP), response rate,(More)
14637 Background: The delivery of CHT in a setting of androgen-independent (AI) PC has demonstrated: survival benefit associated with a PSA decline and tolerable toxicity, thus strongly suggesting that disease modifying potential exists. Preclinical data supports the benefit of simultaneous CHT and androgen deprivation (AD). The stage is set for CHT to be(More)
14584 Background: Genetic alterations targeting the PTEN tumor-suppressive gene are among the most frequently noted mutations in human cancers. Prostate cancer has been reported as a PTEN-null cancer. Absence of functional PTEN in cancer cells leads to activation of downstream components of the P13K pathway, including the Akt and mTOR kinases. Drug(More)
Craniopharyngiomas are rare tumours of the central nervous system. Their successful treatment is marred by a high rate of recurrence and postoperative complications. Their occurrence is sufficiently rare to merit treatment at specialized high volume centers. We have described our experience with these tumours because we feel that published literature is(More)
4533 Background: Immunomodulatory drugs are compounds that originated via the deliberate structural modification of thalidomide. Lenalidomide (Revlimid) is a derivative with enhanced immunological and anti-angiogenic properties lacking toxicities associated with thalidomide. Objectives were to determine response rate, time to progression (TTP), one-year(More)
Objective: To determine the histopathological pattern of glomerular lesions on per-cutaneous renal biopsy in patients presenting with proteinuria. Study Design: Cross-sectional descriptive study. Place and Duration of Study: Department of Medicine, Combined Military Hospital Peshawar, from Aug 2012 to May 2015. Material and Methods: From the adult patients(More)
14624 Background: PPX is a polymer conjugate of paclitaxel. In preclinical studies, PPX has an improved therapeutic profile relative to paclitaxel, in addition demonstrated activity in paclitaxel-resistant tumor models. This study investigates whether single agent PPX can induce PSA responses and increase time to progression in AIPC. METHODS Eligibility(More)
The true incidence of anaphylactic reactions and their associated morbidity and mortality remain poorly defined. This is due to uncertainties in reporting accuracy and exhaustivity. A 23 years old male developed severe anaphylaxis under general anesthesia with cardiovascular collapse, bronchospasm and angio-edema. He was promptly managed with intravenous(More)